Arete Wealth Advisors LLC Invests $86.30 Billion in Tilray Inc (NASDAQ:TLRY)

Arete Wealth Advisors LLC purchased a new position in shares of Tilray Inc (NASDAQ:TLRY – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 34,111 shares of the company’s stock, valued at approximately $86,301,000,000.

Several other large investors also recently modified their holdings of TLRY. JPMorgan Chase & Co. increased its stake in shares of Tilray by 63.2% during the 1st quarter. JPMorgan Chase & Co. now owns 266,929 shares of the company’s stock worth $2,073,000 after purchasing an additional 103,379 shares during the last quarter. Raymond James & Associates increased its stake in shares of Tilray by 7.4% during the 1st quarter. Raymond James & Associates now owns 103,410 shares of the company’s stock worth $803,000 after purchasing an additional 7,135 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Tilray by 77.8% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 148,682 shares of the company’s stock worth $1,155,000 after purchasing an additional 65,079 shares during the last quarter. Cetera Advisor Networks LLC purchased a new stake in shares of Tilray during the 1st quarter worth approximately $82,000. Finally, Private Advisor Group LLC boosted its holdings in Tilray by 25.6% in the 1st quarter. Private Advisor Group LLC now owns 51,937 shares of the company’s stock worth $404,000 after buying an additional 10,587 shares during the period. Hedge funds and other institutional investors own 9.47% of the company’s stock.

Get Tilray alerts:

Tilray Price Performance

Shares of NASDAQ:TLRY opened at $1.69 on Tuesday. The firm has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $2.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.61 and a quick ratio of 1.18. Tilray Inc has a one year low of $1.50 and a one year high of $5.12.

Analyst Upgrades and Downgrades

Several research firms recently commented on TLRY. TD Cowen cut their price objective on shares of Tilray from $9.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, April 11th. Roth Capital reaffirmed a “neutral” rating on shares of Tilray in a report on Wednesday, April 12th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.77.

Tilray Company Profile

(Free Report)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Stories

• Five stocks we like better than Tilray
• How to Invest in Blockchain Stocks Step by Step
• 3 Housing Stocks to Avoid as Interest Rates Rise
• What is a Stock Market Index and How Do You Use Them?
• AMC: Is a Big Squeeze in the Coming Attractions?
• NYSE Stocks Give Investors a Variety of Quality Options 
• Rivian: A Roaring Rise Or Time To Cash Out?

Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Inc (NASDAQ:TLRY – Free Report).

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.